|
Saturday, April 29
8:00am–11:00am
2100—Adult Stem Cells—A Primer for the
Clinician
PAS/ASPHO Mini Course
Room 3014, Moscone West
Chairs: Jakub Tolar, University of Minnesota, Minneapolis, MN; and
Mervin C. Yoder, Jr., Indiana University School of Medicine,
Indianapolis, IN
Target Audience:
Hematologists/oncologists, endocrinologists, basic scientists
and neurologists.
Adult stem cells represent a
technology that is being intensively investigated currently,
and this research may have wide implications for human health.
This mini course will focus on recent research and potential
applications in human health.
-
Introduction
Jakub Tolar, University of Minnesota, Minneapolis, MN
Mervin C. Yoder, Indiana
University School of Medicine, Indianapolis, IN
-
Multipotent Adult Progenitor
Cell: Hype or Reality?
Catherine M. Verfaillie, University of Minnesota, Minneapolis, MN
-
Mesenchymal Stem Cell: Harnessing
the Power of Adult Stem Cells To Repair Tissues
Darwin Prockop, Tulane University Health Science Center, New Orleans,
LA
-
Hierarchy of Endothelial
Progenitors in Human Blood and Blood Vessels
David A. Ingram, Indiana University School of Medicine, Indianapolis,
IN
-
Cancer Stem Cell: Concept of
Human Leukemic Development
Craig T. Jordan, James P. Wilmot Cancer Center, University of Rochester
School of Medicine, Rochester, NY
Sponsored jointly by
the American Society of Pediatric Hematology/Oncology and the
Pediatric Academic Societies
8:00am–11:00am
2120—Management of Childhood Hypertension:
Guidelines and Controversies
PAS/ASPN/IPHA Mini Course
Room 2003-2005, Moscone West
Chairs: Steven R. Daniels, University of Colorado, Denver, CO; and
Ronald J. Portman, University of Texas Medical School,
Houston, TX
Target Audience: General
pediatricians, emergency medicine physicians, hospitalists,
intensivists, nephrologists and cardiologists.
The 2004 NHLBI guidelines for the
evaluation and management of childhood hypertension answered
many questions about how to approach hypertensive children,
but left others unanswered. This mini course is designed to
address some of the more controversial aspects of managing
hypertensive children, with the hope of stimulating further
discussion about the optimal approach to these patients.
Practical approaches to clinical management will be
emphasized.
-
Overview
Stephen R. Daniels, The Children's Hospital/University of Colorado,
Denver, CO
-
Overview of Treatment Guidelines
from the 4th Report
Bonita E. Falkner, Thomas Jefferson University, Philadelphia, PA
-
Management of Pre-hypertension:
Lifestyle Changes or Pharmacologic Treatment?
Shawna D. Nesbitt, University of Texas Southwestern Medical Center,
Dallas, TX
-
Choice of Agent for Children with
Primary Hypertension
Joseph T. Flynn, Children's Hospital at Montefiore, Bronx, NY
-
Treatment of Severe Hypertension
in Ambulatory and Inpatient Settings
Joshua Samuels, University of Texas, Houston, TX
-
Treatment of Hypertension in
Special Populations
Donald L. Batisky, Columbus Children's Hospital/The Ohio State
University College of Medicine, Columbus, OH
-
Discussion
Sponsored jointly by
the American Society of Pediatric Nephrology, the
International Pediatric Hypertension Association and the
Pediatric Academic Societies
8:00am–12:00pm
2180A—LWPES Plenary Session I
LWPES Plenary Session
Room 3007-3009, Moscone West
Chairs: Lynne Levitsky, Massachusetts General Hospital, Boston, MA;
Henry Anhalt, Saint Barnabas Medical Center, Livingston, NJ;
and Alan D. Rogol, University of Virginia, Charlottesville, VA
Target Audience:
Endocrinologists, nephrologists, cardiologists, general
pediatricians, immunologists, geneticists and molecular
biologists.
-
Opening Remarks
Lynne L. Levitsky, Massachusetts General Hospital, Boston, MA
-
Lawson Wilkins Lecture:
Recent years have witnessed a
significant revision of the traditional view of fat cells
as simple stores of excess energy. Studies in the
speaker's lab as well as many others have clearly
demonstrated that adipocytes produce and regulate many
metabolic and hormonal signals, which generate profound
effects on systemic endocrine equilibrium. In his earlier
studies, he also demonstrated that these cells exhibit an
inflammatory capacity that is abnormal in obesity and key
to the pathogenesis of insulin resistance and diabetes.
Recently, he identified a key molecular mechanism
underlying the link between inflammatory responses and
insulin action. This pathway involves obesity-related
activation of the serine, threonine kinase, JNK, and the
consequent inhibition of insulin receptor signaling via
phosphorylation of a substrate of insulin receptor, IRS-1.
-
Integration of Metabolic and
Inflammatory Pathways in Metabolic Disease
Gokhan S. Hotamisligil, Harvard School of Public Health, Boston, MA
-
Robert Blizzard Lecture:
One of the greatest questions
asked of physicians caring for children with autoimmune
diabetes is "why did this happen?" This session
will unravel some of the mysteries surrounding the
etiology and pathogenesis of autoimmune diabetes from an
investigator who has dedicated his life to this issue.
-
On the Unravelling of the
Etiopathogenesis of Type 1 Diabetes: Are We Stuck or
Are We Winning?
Gian Franco Bottazzo, Ospedale Pediatrico Bambino Gesú, Scientific
Institute, Rome, Italy
-
Break
-
Esoterix Lecture:
The attendee will familiarize
him/herself with newer molecular mechanisms of growth
failure that are due to abnormalities in receptor and
post-receptor translation of GH signaling.
-
Molecular Mechanisms and Defects
in Growth Hormone Receptor Signaling
Peter Rotwein, Oregon Health and Science University, Portland, OR
9:45am–11:45am
2200A—Clinical Trials and Observational
Studies
ASPN Workshop
Room 2007, Moscone West
Chairs: Susan L. Furth, Johns Hopkins University, Baltimore, MD; and
Craig Wong, Children's Hospital of New Mexico, Albuquerque, NM
Target Audience: Clinical
investigators and pediatric nephrologists.
This workshop will address
statistical, measurement, ethical and regulatory issues in
clinical research. We will discuss methodological issues in
randomized clinical trials when the sample size is limited, as
often occurs in pediatric studies. We will also address the
measurement of kidney function in large cohort studies.
Finally, we will have an extended discussion on the evolution
of the current regulatory system of clinical research in the
United States. This has evolved from concerns about ethical
issues and protection of subjects to concerns about protection
of the institution through compliance with inflexible
requirements. The session will end with suggestions on what
changes are needed and how to achieve them in the current
regulatory environment.
-
Introduction
Catherine Stehman-Breen, Amgen, Thousand Oaks, CA
-
Methodologic Issues in Clinical
Trials When Sample Size Is Limited
Tom Greene, The Cleveland Clinic, Cleveland, OH
-
Measurement of Glomerular
Filtration Rate in Large Cohort Studies: Design, Conduct
and Analysis
Alvaro Munoz, Bloomberg School of Public Health, Johns Hopkins
University, Baltimore, MD
-
The Dysregulation of Research
Norman Fost, University of Wisconsin Medical School, Madison, WI
Supported by an unrestricted educational grant from the
Kidney and Urology Foundation of America, Inc. (KUFA)
11:45am–2:45pm
2424—Treatment of the Metabolic Syndrome in
Children and Adolescents
PAS Educational Workshop
Golden Gate Hall A1, SF Marriott
Leader: J. Darrell Nesmith, Little Rock, AR; Co-leaders: Alba Morales,
Mohammad Ilyas, Lisa Lubsch
Target Audience:
Endocrinologists, trainees, fellows, junior faculty, mid-level
faculty, senior faculty, and community practitioners.
The rise in pediatric obesity and
metabolic syndrome is well established. Less understood for
the pediatrician is the treatment of the metabolic syndrome.
In this workshop, we aim to: 1) briefly discuss the
epidemiology of the metabolic syndrome in children and
adolescents, 2) discuss non-pharmacologic and pharmacologic
treatment of the metabolic syndrome, and 3) review a stepped
approach in treating adolescents with the metabolic syndrome.
This workshop will be largely
case-based. Come prepared to devise treatment plans in a small
group setting. Participants are invited to bring their own
cases for discussion.
Participants will:
– Learn the epidemiology of the
metabolic syndrome in children and adolescents.
– Become familiar with existing treatment guidelines for
components of the metabolic syndrome in children and
adolescents.
– Identify gaps in the literature regarding treatment
guidelines of the metabolic syndrome in children and
adolescents.
– Consider pharmacologic treatment options of metabolic
syndrome treatment based on the available evidence.
Format: A short didactic
presentation will be given on diabetes, hypertension, and
dyslipidemia treatments from a diabetologist, nephrologist,
and endocrinologist respectively. Existing published
guidelines will be presented while gaps in the literature
regarding treatment will be discussed. Following these short
didactic presentations, small groups (at tables) will work on
cases which will be presented, and a treatment plan will be
derived by each group. At the end of these roundtable work
group discussions, the group as a whole will discuss the
treatment plans. Actual cases will be used when possible (with
appropriate de-identifiers) and their treatment plans
discussed.
12:00pm–1:00pm
2450A—Renal Pathology—Battle of the
Brains
ASPN Luncheon
Room 2007, Moscone West
Chairs: Patrick D. Walker, Nephropathology Associates, Little Rock, AR;
and Victoria F. Norwood, University of Virginia Children's
Medical Center, Charlottesville, VA
Target Audience: American Society
of Pediatric Nephrology members and trainees.
Interactive clinical renal
pathology conference for fellows and selected pediatric
nephrology and pathology faculty during which cases will be
presented for evaluation and spirited discussion. The
objectives are to stimulate interactions between fellows and
members of the society; encourage broad discussions of renal
pathology, pathophysiology and treatment conundrums; and
stimulate the development of potential research questions.
Space is limited.
-
Welcome on Behalf of ASPN
Victoria F. Norwood, University of Virginia Children's Medical Center,
Charlottesville, VA
-
Overview and Keys to the Game
Patrick D. Walker, Nephropathology Associates, Little Rock, AR
Sponsored jointly by The NephCure Foundation and the
American Society of Pediatric Nephrology
12:00pm–3:00pm
2505—Embryonic Stem Cells: A Primer for
Clinicians
PAS Mini Course
Room 3014, Moscone West
Chair: Michael T. Longaker, Stanford University, Stanford, CA
Embryonic stem cells offer
incredible promise for treating diseases affecting both
children and adults. This mini course will provide an overview
of stem cells and a basic understanding of how to derive human
embryonic stem cells, recent research and ethical
considerations. After attending this session, attendee will
have a better understanding of: 1) what are embryonic stem
cells; 2) how human embryonic stem cells are derived; 3)
recent progress in human embryonic stem cell research; 4)
ethical considerations in human embryonic stem cells.
-
Stem Cells: Embryonic, Adult and
Cancer
Michael T. Longaker, Stanford University, Stanford, CA
-
What It Takes Clinically To Get
an Embryonic Stem Cell
Linda C. Giudice, University of California, San Francisco, San
Francisco, CA
-
What Can You Do with an Embryonic
Stem Cell in Research
Renee Reijo Pera, University of California, San Francisco, San
Francisco, CA
-
Ethical and Oversight
Considerations in Human Embryonic Stem Cell Research
Hank Greely, Stanford University, Stanford, CA
-
Panel Discussion
Supported in part by an unrestricted educational grant from
Treuman Katz Center for Pediatric Bioethics - Seattle
Children's Hospital
12:00pm–3:00pm
2510—Inherited Disorders Caused by
Inappropriate Apoptosis
PAS Mini Course
Room 3010, Moscone West
Chairs: Cynthia J. Tifft, Children's National Medical Center,
Washington, DC; and Hans Andersson, Tulane University Medical
Center, New Orleans, LA
Target Audience: Pediatric
researchers interested in genetic basis of disease and
apoptosis.
This session will describe the
recent findings of the role of apoptosis in the pathogenesis
of genetic diseases. Inappropriate apoptosis and acquired
resistance to apoptosis are important mechanisms in some
genetic disorders and a better understanding of this role is
expected to lead to potential therapies.
Inappropriate apoptosis has been
implicated in the causation of several inherited disorders
with specific interest for pediatricians. The pathophysiology
of inherited neurodegenerative disorders have long eluded
explanation and recent studies suggest that storage of
abnormal compounds in lysosomes act as a trigger for
apoptosis. Additionally, nephropathic cystinosis has recently
been shown to be caused by inappropriate onset of apoptosis
caused by abnormal cystinylation. This session will provide a
clinical perspective on the role of apoptosis in genetic
disorders affecting the pediatric population.
-
Overview
Hans C. Andersson, Tulane University Medical School, New Orleans, LA
-
Microglial Activation and
Inflammation Precedes Apoptosis in Tay-Sachs Disease
Cynthia J. Tifft, Children's National Medical Center, Washington, DC
-
Lysosomal Cystine Enhances
Apoptosis and Yields the Nephropathic Cystinotic Phenotype
Jess G. Thoene, Tulane University School of Medicine, New Orleans, LA
-
Niemann Pick Disease, Type C:
Glycolipid Gridlock and Apoptosis
Marc C. Patterson, Columbia University Medical Center, New York, NY
- Role of GM1-Ganglioside
in ER-and Mitochondrial-Mediated Neuronal Apoptosis
Alessandra
D'Azzo, St. Jude Children’s Research Hospital, Memphis,
TN
-
Discussion
1:00pm–3:00pm
2625—Nephrology I
PAS/ASPN Platform Session
Room 2003-2005, Moscone West
Chairs: Patrick D. Brophy and Deepa H. Chand
Includes:
-
ASPN Basic Research Trainee
Award: Deletion of FGFR2 from the Metanephric Mesenchyme
Results in Ectopic Ureteric Bud Induction
David Sullivan Hains, Children's Hospital, Columbus, OH
-
ASPN Clinical Research Trainee
Award: Prevalence of the Stages of Hypertension (HTN) in
Adolescents
Karen L McNiece, University of Texas-Houston Medical School, Houston,
TX
1:30pm–3:30pm
2670A—Controversies in Care in Pediatric
Endocrinology—The Great Debates
LWPES Workshop
Room 3001, Moscone West
Chairs: William Clarke, University of Virginia, Charlottesville, VA;
and Henry Anhalt, St. Barnabas Medical Center, Livingston, NJ
Target Audience:
Endocrinologists, general pediatricians and adolescent
medicine specialists.
The attendee will be part of a
lively debate on a number of areas of controversy in pediatric
state-of-the-art diabetes management.
-
Is Primary Prevention of Type 1
Diabetes Possible?
-
Pro—Desmond A. Schatz, University of Florida, Gainesville, FL
-
Con—Dorothy J. Becker, Children's Hospital of Pittsburgh, Pittsburgh, PA
-
Should Glucose Sensors Be
Routinely Used?
-
Pro—Stuart Alan Weinzimer, Yale School of Medicine, New Haven, CT
-
Con—Darrell M. Wilson, Stanford University Medical Center, Stanford, CA
-
Should Metformin Be Used To Treat
Pediatric Patients with Insulin Resistance?
-
Pro—Michael S. Freemark, Duke University Medical Center, Durham, NC
-
Con—Philip Scott Zeitler, University of Colorado at Denver and Health
Sciences Center, Denver, CO
2:15pm–5:15pm
2700—Educating Pediatric Fellows in a
Competency-Based World
PAS/APPD Mini Course
Room 2007, Moscone West
Chairs: Susan Guralnick, Stony Brook University Medical Center, Stony
Brook, NY; and Joseph Gilhooly, Oregon Health and Science
University, Portland, OR
Target Audience: Attendees
involved with fellowship programs.
Competency-based education is now
the standard for residency education. Residency programs have
integrated the ACGME Core Competencies into their curricula
and assessment methods. It is now time for fellowships to
enter the “competency” arena, and there is much to be
accomplished. This program will focus on several areas of
fellowship education including: the new RRC common
requirements for subspecialty training, development of a
competency-based fellowship curriculum, competency-based
assessment tools, and pediatric subspecialty fellows as
teachers. Attendees are encouraged to bring tools and ideas
for discussion and development. Attendees should leave with
useful materials to bring back to their home programs.
-
Overview
Susan Guralnick, Stony Brook University Medical Center, Stony Brook, NY
Joseph Gilhooly, Oregon Health
& Science University, Portland, OR
-
A Brave New World! New Common
Requirements for Subspecialty Training—Implementing the
Competencies
Carol Carraccio, Professor of Pediatrics and Associate Chair for
Education, University of Maryland School of Medicine,
Baltimore, MD
-
"Survivor ACGME"—Fellowship
Competencies in Action
Joseph Gilhooly, Oregon Health & Science University, Portland, OR
John D. Mahan, Children’s
Hospital, The Ohio State University, Columbus, OH
-
Turning to Fellows as Teachers:
From Curricula to Evaluation
Nancy D. Spector, St. Christopher's Hospital for Children,
Philadelphia, PA
Susan Guralnick, Stony Brook
University Medical Center, Stony Brook, NY
Sponsored jointly by
the Lawson Wilkins Pediatric Endocrine Society and the
Pediatric Academic Societies
2:15pm–5:15pm
2705—Vitamin D: More Than Just Calcium and
Bone
PAS/LWPES Mini Course
Room 3007-3009, Moscone West
Chairs: Catherine M. Gordon, Children's Hospital of Boston, Boston, MA;
and Linda A. DiMeglio, Indiana University, Indianapolis, IN
Target Audience: General
pediatricians, gastroenterologists, endocrinologists and
hematologists/oncologists.
The understanding of the role of
vitamin D in health and illness is becoming more complex. Both
skeletal and extra-skeletal actions have been described, and
vitamin D analogs are being explored for their anti-proliferative
effects. The attendee will gain both clinically relevant
epidemiological knowledge as well as review the calcemic and
non-calcemic actions of Vitamin D.
-
What Is the Evidence for Vitamin
D Deficiency in Children?
Frank R. Greer, University of Wisconsin, Madison, WI
-
Vitamin D and Extra-Skeletal
Actions in Health
Michael F. Holick, Boston University School of Medicine, Boston, MA
-
Non-calcemic Actions of Vitamin D
Receptor Ligands
Sunil Nagpal, Women's Health & Musculoskeletal Biology,
Collegeville PA
Sponsored jointly by
the Lawson Wilkins Pediatric Endocrine Society and the
Pediatric Academic Societies
3:15pm–5:15pm
2730—Mechanisms of Hypertension in the
Molecular Era
PAS/ASPN/IPHA/LWPES Topic Symposium
Room 2003-2005, Moscone West
Chairs: Bruce Z. Morgenstern, Phoenix Children's Hospital, Phoenix, AZ;
and Julie R. Ingelfinger, Massachusetts General Hospital,
Boston, MA
Target Audience: General
pediatricians, nephrologists, endocrinologists and
neonatologists.
Our understanding of the
pathophysiology of hypertension has been changing rapidly due
to advances in molecular genetics, most notably the
identification of several single-gene defects that cause
hypertension. This session will update participants on the
latest advances in our knowledge of molecular mechanisms of a
variety of forms of hypertension.
-
Role of Dopamine Receptors
Pedro A. Jose, Georgetown University Medical Center, Washington, DC
-
Perinatal Programming and the
Development of Hypertension
Lori Woods, Oregon Health & Science University, Portland, OR
-
Low Renin Hypertension in
Childhood
Maria I. New, Mount Sinai School of Medicine, New York, NY
-
WNK Kinases and Blood Pressure
Regulation
Richard Lifton, Yale University School of Medicine, New Haven, CT
Sponsored jointly by
the American Society of Pediatric Nephrology, the
International Pediatric Hypertension Association, the Lawson
Wilkins Pediatric Endocrine Society and the Pediatric Academic
Societies
3:15pm–5:15pm
2735—Update on Therapeutic Monoclonal
Antibodies
PAS Topic Symposium
Room 3014, Moscone West
Chair: E. Richard Stiehm, UCLA School of Medicine, Los Angeles, CA
Target Audience: Immunologists,
rheumatologists, hematologists, oncologists and general
pediatricians.
The first talk will be an
overview of the various therapeutic monoclonals and some
general principles of their use. Then a discussion of
Rituximab in refractory immune cytopenias and other disorders
will be presented. Then the use of anti-tumor necrosis factor
treatment including infliximab and adalimumab (Ramicade and
Humira) for rheumatic diseases in children. The final talk
will discuss the adverse effects of these therapies and some
projections for the future. Discussion will be held after each
presentation.
-
Overview
E. Richard Stiehm, Mattel Children's Hospital at UCLA, Los Angeles, CA
-
Use of Anti-CD20 (Rituximab) in
Hematology and Autoimmunity
James B. Bussel, New York Hospital, Cornell Medical Center, New York,
NY
-
Use of Anti-TNF and Other
Cytokine Inhibitors in Rheumatology and Related Illnesses
Christy Irene Sandborg, Stanford University Medical Center, Stanford,
CA
-
The Downside and Future of
Monoclonal Antibody Therapy
Susan Lee, University of California, San Diego, CA
4:00pm–7:30pm
Commercial Exhibits Open and Posters
Available for Viewing
PAS Exhibits
Levels 1 and 2, Moscone West
Posters Available for Viewing:
4:00pm–7:30pm
Author Attendance: 5:15pm–7:15pm
Level 1:
– Developmental Biology
– Endocrinology
– Hematology–Oncology
– Neonatal Infectious Diseases
– Neonatology
– Nephrology
Level 2:
– Cardiology
– Developmental–Behavioral Pediatrics
– General Pediatrics
– Medical Education
– Neurology
5:15pm–6:00pm
2800—Clinical Pediatric Hypertension
PAS/ASPN/IPHA Poster Symposium
Room 2004, Moscone West
Chairs: Stephen R. Daniels and Deborah P. Jones
5:15pm–7:15pm
Poster Session I and PAS Opening Reception
PAS Poster Session
Levels 1 and 2, Moscone West
Level 1:
– Developmental Biology
– Endocrinology
– Hematology–Oncology
– Neonatal Infectious Diseases
– Neonatology
– Nephrology
Level 2:
– Cardiology
– Developmental–Behavioral Pediatrics
– General Pediatrics
– Medical Education
– Neurology
Includes
-
SPR Student Research Award:
Resuscitation of Non-Viable Infants: Will
Neonatologists[apos] Practice Change After the Born-Alive
Infant Protection Act?
Mya Sendowski, University of California, San Francisco, CA
8:00pm–10:00pm
2980A—ASPN Member Reception
ASPN Dinner
Room View Lounge, SF Marriott
– Fellow Awards
– Welcome Residents
Presenter—Research Trainee
Awards
Susan L. Furth, Johns Hopkins University, Baltimore, MD
Sunday, April 30
7:00am–8:00am
3050—Life as a Pediatric Nephrologist
PAS Meet the Professor
Yerba Buena Gardens Salon 11, SF Marriott
This session is intended to
provide trainees and junior faculty with insights about career
opportunities in pediatric nephrology and appropriate
preparation for these careers. Career opportunities, both
within and outside of academic departments, will be discussed.
Faculty tracks and the perspective of department chairs about
these tracks will also be addressed. Topics will include how
to choose the appropriate academic position for one’s
interests and talents, as well as balancing career objectives
with personal and family goals.
8:00am–10:00am
3115A—Renal Pathology—Its Still Not Just
Little Adults
ASPN Symposium
Room 2003-2005, Moscone West
Chairs: Sharon P. Andreoli, James Whitcomb Riley Hospital for Children,
Indiana University Medical Center, Indianapolis, IN; and
Patrick Walker, Nephropathology Associates
Target Audience: Nephrologists
and pathologists.
The pathologic features of the
kidney in pediatric kidney disease have unique features
compared to adult patients and, some kidney diseases are
solely observed in pediatric patients. This symposia will
address the unique pathologic features of congenital nephrotic
syndrome, MPGN, renal pathology in pediatric transplant
patients and will also propose a new taxonomy for the
podocytopathies.
-
Congenital Nephrotic
Syndrome—An Update
Stephen M. Bonsib, James Whitcomb Riley Hospital for Children, Indiana
University Medical Center, Indianapolis, IN
-
MPGN and Dense Deposit Disease
Patrick D. Walker, Nephropathology Associates, Little Rock, AR
-
Renal Pathology in Pediatric
Transplant Patients
Carole A. Vogler, Saint Louis University, St. Louis, MO
-
Toward a New Taxonomy for the
Podocytopathies
Laura Barisoni, New York University School of Medicine, New York, NY
12:00pm–1:30pm
3430A—ASPN Business Meeting, Luncheon and
Presidential Address
ASPN Presidential Lecture
Yerba Buena Gardens Salon 7, SF Marriott
-
ASPN Presidential Address
Sandra L. Watkins, Children's Hospital and Regional Medical Center,
Seattle, WA
2:00pm–4:00pm
3728—Nephrology II
PAS/ASPN Platform Session
Room 2003-2005, Moscone West
Chairs: Jeffrey Leiser and Scott K. Van Why
Includes:
-
ASPN Basic Research Trainee
Award: Insulin-Like Growth Factor Receptor (IGF1-R) and
Glomerular Integrity
Janis Dionne, British Columbia Children's Hospital, Vancouver, CA
-
ASPN Clinical Research Trainee
Award: Characterization of a Novel Biomarker Panel for
Acute Kidney Injury
Mai Thanh-Thuy Nguyen, Cincinnati Children's Hospital, Cincinnati, OH
4:15pm–5:45pm
3805—Fetal Homeland Security: New Insights
into Old Threats
PAS State of the Art Plenary
Room 3002-3008, Moscone West
Chairs: Phil W. Shaul, University of Texas Southwestern Medical Center,
Dallas, TX; and Rashmin C. Savani, University of Texas
Southwestern Medical Center, Dallas, TX
Target Audience: Neonatologists,
pediatricians and researchers interested in perinatal biology.
In addition to premature birth,
there are a select number of maternal conditions that have
marked negative impact on the well being of the fetus and
newborn. This symposium will highlight recent advances in our
understanding of these classical threats to our most
vulnerable pediatric patient population.
First, new knowledge of the
mechanisms by which maternal diabetes alters embryonic and
fetal development will be discussed. Second, the newly
discovered role of circulating anti-angiogenic proteins of
placental origin in the pathogenesis of preeclampsia will be
presented. Finally, novel mechanisms by which biochemical
events in the fetal lung trigger the initiation of labor will
be discussed. Further advances in each of these realms will
ultimately lead to new therapies to protect the fetus and
yield healthy outcomes at term.
-
Mechanisms by Which Maternal
Diabetes Modifies Embryonic and Fetal Development
Kelle H. Moley, Washington University School of Medicine, St. Louis, MO
-
Role of Circulating Anti-angiogenic
Proteins of Placental Origin in the Pathogenesis of
Preeclampsia
S. Ananth Karumanchi, Harvard Medical School, Beth Isreal Deaconess
Medical Center, Boston, MA
-
Fetal–Maternal Signaling in the
Initiation of Labor
Carole R. Mendelson, University of Texas Southwestern Medical Center,
Dallas, TX
4:15pm–5:45pm
3810—RNA Interference, Technological
Development of siRNAs and Potential Treatments for Childhood
Diseases
PAS State of the Art Plenary
Room 3016-3018, Moscone West
Chair: R. Alan B. Ezekowitz, Harvard Medical School, Massachusetts
General Hospital, Boston, MA
Target Audience: Basic scientists
studying a broad range of childhood diseases, translational
scientists of all disciplines studying clinical implications
of basic science research, clinical scientists studying
childhood and other diseases in need of improved therapies and
clinicians interested in cutting-edge science and its medical
implications.
RNA interference is a recently
discovered, naturally occurring intracellular process that
regulates gene expression through the silencing of specific
mRNAs. Methods of harnessing this natural pathway are being
developed that allow the catalytic degradation of targeted
mRNAs using specifically designed complementary small
inhibitory RNAs (siRNA). siRNAs are being chemically modified
to acquire drug-like properties. Numerous recent high-profile
publications have provided proofs of concept that RNA
interference may be useful therapeutically. Much of the design
of these siRNAs can be accomplished bioinformatically, thus
potentially expediting drug discovery and opening new avenues
of therapy for many childhood diseases including uncommon
pediatric and orphan diseases. A discussion of the science
behind RNA interference will be followed by a presentation of
the potential practical issues in applying this technology to
disease. The program then describes two therapeutic programs
currently under way with applications to pediatric diseases. A
question-and-answer time will follow each discussion.
-
The Science of RNA Interference
John J. Rossi, Beckman Research Institute of City of Hope, Duarte, CA
-
RNA Interference and Its
Potential Applications for Controlling Disease
Judy Lieberman, CBR Institute for Biomedical Research and Harvard
Medical School, Boston, MA
-
Silencing the VEGF Pathway with
siRNAs and the Potential Application to Retinopathy of
Prematurity
Pamela Pavco, Sirna Therapeutics, Boulder, CO
-
siRNA as Therapy for Respiratory
Syncytial Virus
John P. DeVincenzo, University of Tennessee School of Medicine,
Memphis, TN
4:15pm–6:15pm
3825A—Systemic Lupus: Implications of
Recent Developments for Management of Children with Lupus
Nephritis
ASPN Symposium
Room 2003-2005, Moscone West
Chairs: Joseph T. Flynn, Montefiore Medical Center, Bronx, NY; and
James Jarvis, University of Oklahoma Health Sciences Center,
Oklahoma City, OK
Target Audience: Nephrologists
and rheumatologists.
Glomerulonephritis remains a
significant source of morbidity in children with SLE. However,
recent changes in renal pathology and immunosuppressive
regimens offer the potential for improved outcomes in affected
children. This session will highlight some of the recent
advances in the diagnosis and treatment of children with lupus
nephritis.
-
Overview
Joseph T. Flynn, Children's Hospital at Montefiore, Bronx, NY
James N. Jarvis, University of
Oklahoma Health Sciences Center, Oklahoma City, OK
-
Updated WHO Classification
System: Are There Implications for Therapy?
Glen S. Markowitz, Columbia University Medical Center, New York, NY
-
Application of Monoclonal
Antibodies in Therapy: Rituximab and Beyond
Sangeeta Sule, Johns Hopkins University, Baltimore, MD
-
Cyclophosphamide Versus
Mycophenolate as Initial Therapy for Class III and IV
Lupus Nephritis
Ana L. Paredes, Miami Children's Hospital, Miami, FL
Sponsored jointly by
the AAP Section on Rheumatology and the American Society of
Pediatric Nephrology
Monday, May 1
8:00am–10:00am
4110—Pediatric Fluids and Hyponatremia: Are
We Giving Too Much Water?
PAS/ASPN/LWPES Topic Symposium
Room 3007-3011, Moscone West
Chairs: John W. Foreman, Duke University Medical Center, Durham, NC;
and D. Michael Foulds, University of Texas Health Science
Center at San Antonio, San Antonio, TX
Target Audience: Nephrologists,
general pediatricians, emergency room doctors, intensivists,
hospitalists, endocrinologists and anyone who administers IV
maintenance fluids.
In the 1950s, Holiday and Segar
devised formulae for calculating intravenous maintenance
fluids for infants and children who were unable to drink.
These formulae have been taught and used now for over 40 years
and have generally stood the test of time. However, several
recent investigators have challenged these formulae and argued
that they put children at risk of hyponatremia. Since Holiday
and Segar devised these formulae, new information has arisen,
such as the concept of non-osmotic stimulation of ADH release
in sick children and our ability to measure ADH levels in
plasma on a routine basis. Arieff and Ayus were the first to
point out that children and women are at particular risk for
developing hyponatremic encephalopathy. Moritz and Ayus have
subsequently argued that hypotonic parenteral fluid should not
be used unless there are ongoing free water losses or
hypernatremia. In addition to this new clinical data,
Verkman’s group has exciting data identifying molecular
mechanisms of cerebral edema, including after water
intoxication. Dr. Arieff will review who is at risk and why.
Dr. Verkman’s group has developed data regarding mechanisms
of cerebral edema in experimental animals. Dr. Moritz will
describe the new concepts of maintenance fluids. Dr. Friedman
will defend the current practice. At the end there will be
time for an exchange between the speakers and the audience on
the right fluid to use in today’s children.
-
Hyponatremic Encephalopathy:
Special Risk Factors for Children and Women
Allen I. Arieff, University of California San Francisco, San Francisco,
CA
-
Aquaporin 4 and Cerebral Edema
Alan S. Verkman, University of California San Francisco, San Francisco,
CA
-
0.9% Sodium Chloride: The New
Approach to Maintenance Fluids in Pediatrics
Michael L. Moritz, Children's Hospital of Pittsburgh, Pittsburgh, PA
-
Maintenance Therapy: Tried and
True
Aaron L. Friedman, Brown Medical School, Hasbro Children's Hospital,
Providence, RI
Sponsored jointly by
the AAP Section on Nephrology, the American Society of
Pediatric Nephrology, the Lawson Wilkins Pediatric Endocrine
Society and the Pediatric Academic Societies
12:00pm–1:00pm
4400A—ASPN Awards Luncheon
ASPN Luncheon
Yerba Buena Gardens Salon 7, SF Marriott
12:00pm–6:45pm
Commercial Exhibits Open and Posters
Available for Viewing
PAS Exhibits
Levels 1 and 2, Moscone West
Posters Available for Viewing:
12:00pm–6:45pm
Author Attendance: 5:15pm–6:45pm
Level 1:
– Critical Care
– Gastroenterology
– Genetics
– Neonatal Epidemiology and Follow Up
– Neonatal Pulmonology
– Neonatology
– Nephrology
– Pulmonology
Level 2:
– Developmental–Behavioral Pediatrics
– Emergency Medicine
– General Pediatrics
– Medical Education
1:00pm–2:45pm
4500—March of Dimes Prize in Developmental
Biology Lecture
PAS Award
Room 3002-3008, Moscone West
Dr. Varshavsky is a pioneer in
the study of ubiquitin, a tiny protein that has a very big
job. Ubiquitin (from the Latin ubique meaning
"everywhere," the source of the word
"ubiquitous") is so named because it is essential to
nearly every major activity in the life cycle of cells,
including cell growth and division during embryo development,
DNA repair, programmed cell death, immune response, and the
nervous system. The ubiquitin system is the housekeeping
mechanism by which the cell maintains a proper and healthy
balance of proteins. Ubiquitin's role was unknown until the
1980s, when Dr. Varshavsky and colleagues elucidated it. This
discovery revolutionized our understanding of the control of
human cells, and ubiquitin quickly became one of the major
areas of study in genetics, developmental biology, cell
biology, and biochemistry. Today ubiquitin is a cornerstone of
medical research into the causes and treatments of birth
defects, neurodegenerative disease, infections, and cancer.
Dr. Varshavsky receives the 2006 March of Dimes Prize for
revealing and characterizing the biological significance of
the ubiquitin system in the regulation of living cells.
-
Regulation by Proteolysis: The
N-End Rule Pathway in Yeast and Mammals
Alexander Varshavsky, Smits Professor of Cell Biology, California
Institute of Technology, Pasadena, CA
Presented by the
March of Dimes Birth Defects Foundation
3:00pm–5:00pm
4630A—Molecular Control of the Formation of
the Renal Collecting System
ASPN Symposium
Room 3010-3012, Moscone West
Chairs: Lisa M. Satlin, Mount Sinai School of Medicine, New York, NY;
and Norman D. Rosenblum, The Hospital for Sick Children,
Toronto, Ontario, Canada
Target Audience: Clinicians,
clinician-scientists and scientists interested in development,
nephrology and human disease involving the urinary tract.
Kidney development depends on
embryonic processes which pattern the collecting system
consisting of the ureter, renal pelvis and calyces, and
collecting ducts. Disruption of these processes in humans
results in a spectrum of anomalies including vesicoureteral
reflux, malformations of the pelvis and calyces, a decreased
number of collecting ducts and cystic malformation of these
ducts. Presentations in this symposium will highlight newly
elucidated genetic mechanisms that control different aspects
of collecting system formation. Analyses of genetic mouse
models are demonstrating a critical role for Fibroblast Growth
Factor Receptors in controlling growth and branching of the
ureteric buds that give rise to collecting ducts. Recent
evidence reveals a critical role for HNF1b, a transcription
factor, in controlling collecting duct terminal
differentiation and cyst formation via mechanisms involving
PKDH1, the gene mutated in human autosomal recessive kidney
disease. New genetic approaches are being harnessed to define
molecular mechanisms that control formation of the
vesico-ureteric orifice. Together, these discoveries and
approaches are providing novel molecular insights into
developmental nephrology and human disease.
-
Overview
Norman D. Rosenblum, Professor of Paediatrics and Canada Research Chair
in Developmental Nephrology, Division of Nephrology &
Program in Developmental Biology, The Hospital for Sick
Children, Toronto, Ontario, Canada
-
Role of Fibroblast Growth Factor
Receptors in Kidney Development
Carlton M. Bates, Children's Hospital of Columbus, Columbus, OH
-
Transcriptional Control of the
Bradykinin B2 Receptor
Samir S. El-Dahr, Tulane University School of Medicine, New Orleans, LA
-
Roles of HNF-1beta in Kidney
Development and Disease
Peter Igarashi, University of Texas Southwestern School of Medicine,
Dallas, TX
-
Genes and VUR
Ali Gharavi, Columbia University, New York, NY
5:15pm–6:45pm
Poster Session III
PAS Poster Session
Levels 1 and 2, Moscone West
Level 1:
– Critical Care
– Gastroenterology
– Genetics
– Neonatal Epidemiology and Follow Up
– Neonatal Pulmonology
– Neonatology
– Nephrology
– Pulmonology
Level 2:
– Developmental–Behavioral Pediatrics
– Emergency Medicine
– General Pediatrics
– Medical Education
Tuesday, May 2
8:00am–10:00am
5110A—Inflammation in Uremic
Pathophysiology
ASPN Symposium
Room 3010-3012, Moscone West
Chairs: H. William Schnaper, Northwestern University Feinberg School of
Medicine, Chicago, IL; and Robert H.K. Mak, Oregon Health and
Science University, Portland, OR
Target Audience: Pediatric
nephrologists and fellows, basic scientists, pathologists and
immunologists.
Recent evidence has strongly
suggested that the manifestations of uremia are caused in
large part by activation of inflammatory pathways. This
symposium will review the syndromic events that can be
attributed to uremic inflammation and include oxidant injury,
cytokine production and its end-organ effects on the body
tissues.
-
Oxidant Injury in ESRD
Jonathan Himmelfarb, Maine Medical Center, Portland, ME
-
MIA (Malnutrition, Inflammation,
Atherosclerosis) Syndrome in ESRD
Joel D. Kopple, Harbor-UCLA Medical Center, David Geffen School of
Medicine at UCLA, UCLA School of Public Health, Torrance,
CA
-
Leptin and Melanocortin Signaling
in Chronic Kidney Disease
Robert H.K. Mak, Oregon Health and Science University, Portland, OR
-
Molecular Pathophysiology of
Muscle Catabolism in Uremia: Effect of Acidosis and
Inflammation
William E. Mitch, Baylor College of Medicine, Houston, TX
Supported by an unrestricted educational grant from Abbott
10:00am–12:00pm
5360A—Pay for Performance: The Pediatric
Perspective—Hemodialysis
ASPN Workshop
Room 3010-3012, Moscone West
Chairs: Sandra L. Watkins, Children's Hospital and Regional Medical
Center, Seattle, WA; and Bradley A. Warady, Children's Mercy
Hospital and Clinics, Kansas City, MO
Target Audience: Nephrologists.
Quality patient care is of utmost
importance to pediatricians caring for children. Congress and
the Centers for Medicare and Medicaid are exploring models of
“Pay for Performance” in an effort to reward high quality
patient care and encourage ongoing quality improvement. This
workshop explores the latest research results that aid the
clinician in improving patient outcomes in hemodialysis,
reviews the data available linking performance measures and
outcomes and discusses the mechanisms for reimbursement.
-
Overview
Bradley A. Warady, Children's Mercy Hospital and Clinics, Kansas City,
MO
-
New Insights into Improved
Quality Care in Hemodialysis
Stuart L. Goldstein, Baylor College of Medicine/Texas Children's
Hospital, Houston, TX
-
Quality Measures for Pediatric
Hemodialysis—What Should They Be?
Barbara Fivush, Johns Hopkins University, Baltimore, MD
-
How Can a Pediatric Nephrologist
be Appropriately Compensated for Providing Quality
Hemodialysis Care?
Linda Upchurch, Baxter Healthcare Corporation, Fletcher, NC
-
Discussion
Sponsored jointly by
the North American Pediatric Renal Transplant Cooperative
Study (NAPRTCS) and the American Society of Pediatric
Nephrology
1:45pm–3:45pm
5720—Autosomal Recessive Polycystic Kidney
Disease (ARPKD): New Insights and Clinical Perspectives
PAS/ASPN/NASPGHAN Topic Symposium
Room 3010-3012, Moscone West
Chairs: Philip Rosenthal, University of California, San Francisco, San
Francisco, CA; and Lisa M. Guay-Woodford, University of
Alabama at Birmingham, Birmingham, AL
Target Audience: Pediatricians,
pediatric nephrologists, pediatric gastroenterologists,
neonatalogists and developmental biologists.
ARPKD is a developmental disorder
of the kidneys and liver caused by mutations in the PKHD1
gene. Fibrocystin/polyductin, the protein encoded by PKHD1, is
expressed on the primary cilia of renal and bile duct
epithelial cells. Several lines of evidence indicate that the
PKHD1 transcriptional profile is complex with extensive splice
variants. While the function of these transcripts and the
polypeptides that they encode is not well understood, these
proteins seem to play critical roles in establishing and
maintaining the tubular architecture. This symposium will
discuss the complex transcriptional profile of PKHD1 and the
role of these gene products in renal as well as biliary
epithelia. Given that ARPKD has a high perinatal mortality due
to oligohydramnios and resultant respiratory insufficiency,
current concepts regarding the interplay between the
developing kidney, the placenta and the developing lung will
be discussed. Finally, a clinical perspective based on the
on-going NHGRI-sponsored natural history study will focus on
ARPKD-associated morbidities and disease progression.
-
Transcriptional Complexity of
PKHD1: Implications for Development and Disease
Pathogenesis
Gregory G. Germino, Johns Hopkins University, Baltimore, MD
-
Pathobiology of Biliary Epithelia
in ARPKD
Tatyana Masyuk, Mayo Clinic College of Medicine, Rochester, MN
-
Oligohydramnios: Current Concepts
and Implications for Pulmonary Development
F. Sessions Cole, Washington University School of Medicine, St. Louis
Children's Hospital, St. Louis, MO
-
Report on the NIH ARPKD/CHF
Natural History Study
Meral Gunay-Aygun, National Human Genome Research Institute (NHGRI),
Bethesda, MD
Sponsored jointly by
the American Society of Pediatric Nephrology; the North
American Society for Pediatric Gastroenterology, Hepatology
and Nutrition; and the Pediatric Academic Societies
|
